Is MOH a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Molina Healthcare (MOH) rests on Medicaid rate catch-up: Molina's margins depend on states adjusting per-member rates to reflect actual medical costs. Revenue (TTM) is ~$43B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The central risk is that elevated medical utilization and retroactive Medicaid adjustments keep outpacing state rate increases, keeping the medical care ratio high and margins compressed longer than expected. Whether MOH is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Molina Healthcare is a Fortune 500 managed-care organization that provides health coverage almost exclusively through government-sponsored programs. It runs four segments (Medicaid, Medicare, Marketplace, and Other) and serves roughly 5.6 million members, with about 90% in Medicaid. Its model is to specialize in low-income, senior, and disabled populations, winning state Medicaid contracts and managing medical costs tightly rather than competing in commercial employer insurance. Revenue is dominated by premiums the states and federal government pay per member, so growth comes from new contract wins, acquisitions, and membership rather than pricing power. The investment picture in 2026 is defined by a cost shock. In late 2025 Molina reported a surprise quarterly loss and cut 2026 adjusted earnings guidance dramatically (to at least ~$5.00 per share from prior expectations above ~$14), and the stock fell roughly 28%. The core problem is that medical utilization and retroactive Medicaid adjustments outran the rates states were paying, pushing the medical care ratio into the low 90s percent. Q1 2026 showed an adjusted earnings beat but a still-elevated cost ratio, plus a charge tied to exiting an underperforming Medicare Part D product for 2027. Bulls see a cyclical margin recovery as states re-rate contracts higher; the risk is that elevated costs persist and compress margins for longer.
What's the case for buying MOH?
1. Medicaid rate catch-up
Molina's margins depend on states adjusting per-member rates to reflect actual medical costs. Management's thesis is that 2026-2027 rate cycles re-price contracts higher after a period where costs outran reimbursement. If that catch-up materializes, the medical care ratio can drift back toward historical norms and adjusted earnings can recover from the reset base.
2. Contract wins and membership growth
Growth for a Medicaid specialist comes from winning new state procurements, entering new geographies, and bolt-on acquisitions rather than raising prices. Molina has historically expanded premium revenue through new contracts even as some legacy Medicaid redeterminations trim membership. 2026 premium revenue is guided to roughly $42 billion despite a projected membership decline.
3. Portfolio pruning and cost discipline
The company is exiting its underperforming Medicare Advantage Part D product for 2027 and taking associated charges, a signal it is willing to shed low-margin business. Tighter operating discipline and a focus on higher-quality government contracts are central to management's plan to rebuild margins.
4. Structural demand for government coverage
Managed Medicaid and Medicare Advantage continue to see long-run enrollment demand as states outsource care management and the eligible population ages. This gives Molina a large, recurring addressable base even through near-term earnings volatility.
What are the risks to MOH?
The central risk is that elevated medical utilization and retroactive Medicaid adjustments keep outpacing state rate increases, keeping the medical care ratio high and margins compressed longer than expected. Molina is heavily exposed to political and regulatory decisions: potential cuts to Medicaid funding, changes to ACA Marketplace subsidies, and eligibility redeterminations can each shrink membership or reimbursement. Revenue concentration in a handful of large state contracts means losing a re-procurement can be material. The 2026 guidance cut and prior loss show earnings can swing sharply and unpredictably. Competition from larger, better-capitalized insurers (Centene, UnitedHealth, Elevance, Humana, CVS/Aetna) pressures bids and margins.
How is MOH valued? (as of JULY 2026)
Snapshot for MOH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$43B
- 2026 premium revenue (guided): ~$42B
- 2026 adjusted EPS (guided): at least ~$5.00
- Q1 2026 medical care ratio: ~91%
- Market cap: ~$12B
- Members: ~5.6M
MOH shares fell roughly 28% in early 2026 after a surprise quarterly loss and a steep cut to 2026 adjusted earnings guidance. The reported P/E looks distorted (very high on depressed trailing GAAP earnings, lower on forward views), so the market is valuing it on a hoped-for margin recovery rather than trailing profits. The key metric to watch is the medical care ratio versus state rate updates.
How do you decide if MOH is a buy?
Rather than asking whether MOH is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MOH indirectly through an index or sector ETF before adding more.
For the full picture, see the MOH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MOH against your real portfolio and see your actual exposure before deciding.
The bottom line on MOH
The bottom line: Molina Healthcare's story right now is Medicaid rate catch-up, with revenue (ttm) at ~$43B. If you believe that narrative continues, the call is about sizing MOH sensibly and checking overlap with what you own; if you doubt it (the risk: the central risk is that elevated medical utilization and retroactive Medicaid adjustments keep outpacing state rate increases, keeping the medical care ratio high and margins compressed longer than expected.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around MOH with Walnut
Use Molina Healthcare as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is MOH a good stock to buy right now?
+
The case for Molina Healthcare right now is Medicaid rate catch-up, with revenue (ttm) at ~$43B. If you believe that thesis holds, MOH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the central risk is that elevated medical utilization and retroactive Medicaid adjustments keep outpacing state rate increases, keeping the medical care ratio high and margins compressed longer than expected. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Molina Healthcare do?
+
Molina Healthcare is a Fortune 500 managed-care organization that provides health coverage almost exclusively through government-sponsored programs.
What are the main risks of MOH?
+
The central risk is that elevated medical utilization and retroactive Medicaid adjustments keep outpacing state rate increases, keeping the medical care ratio high and margins compressed longer than expected. Molina is heavily exposed to political and regulatory decisions: potential cuts to Medicaid funding, changes to ACA Marketplace subsidies, and eligibility redeterminations can each shrink membership or reimbursement. Revenue concentration in a handful of large state contracts means losing a re-procurement can be material. The 2026 guidance cut and prior loss show earnings can swing sharply and unpredictably. Competition from larger, better-capitalized insurers (Centene, UnitedHealth, Elevance, Humana, CVS/Aetna) pressures bids and margins.
What does Molina Healthcare do?
+
Molina is a managed-care insurer that provides health coverage almost entirely through government programs: Medicaid, Medicare Advantage, and ACA Marketplace plans. It serves about 5.6 million members, roughly 90% of them in Medicaid, focusing on low-income, senior, and disabled populations.
Why did MOH stock fall in 2026?
+
In late 2025 Molina reported a surprise quarterly loss and cut its 2026 adjusted earnings guidance sharply (to at least ~$5.00 per share), citing elevated medical costs and retroactive Medicaid adjustments. Shares dropped about 28% on the news.
What is the medical care ratio and why does it matter?
+
The medical care ratio (MCR) is the share of premium revenue spent on medical claims. A higher MCR means less is left for profit. Molina's MCR climbed into the low 90s percent in recent quarters, which is the core reason margins and earnings came under pressure.
How does Molina make money?
+
States and the federal government pay Molina fixed premiums per enrolled member. Molina profits when it manages members' medical costs below those premiums. Growth comes mainly from winning new state contracts, entering new geographies, and acquisitions, not from raising prices.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell MOH; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.